KPTIQ — Karyopharm Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1503802 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 33,432,000 32,347,000 -22,526,000 -67,023,000 111,317,000 54,980,000 441,485,000
Mar 2026 35,066,000 33,721,000 -26,760,000 -22,392,000 131,417,000 90,850,000 397,063,000
Dec 2025 34,079,000 32,595,000 -17,844,000 -102,198,000 108,416,000 60,540,000 401,342,000
Sep 2025 44,044,000 41,931,000 -15,220,000 -33,127,000 96,232,000 37,672,000 365,490,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-65,347,000
Investing CF
$2,969,000
Financing CF
$78,596,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.09
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,848,914,000
Inventory
$3,994,000
Receivables
$29,871,000
ST Investments
$10,125,000
EBIT TTM
$-175,448,000
Pretax Income TTM
$-224,772,000
Interest Exp TTM
$49,324,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$146,620,992
EBITDA
$-82,201,000
Free Cash Flow
$-29,674,250
Enterprise Value
$263,821,920
Total Cash
$65,105,000
Total Debt
$328,529,984
Shares Out
—
Trailing EPS
—
Book Value
$-14.56
ROE
—
ROA
-47.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 146,067,000 -90,707,000 -196,039,000 108,416,000 401,342,000 -292,926,000 -75,369,000
Dec 2024 145,237,000 -119,443,000 -76,422,000 164,418,000 350,435,000 -186,017,000 -127,486,000
Dec 2023 146,033,000 -129,540,000 -143,099,000 240,438,000 376,644,000 -136,206,000 -92,723,000
Dec 2022 157,074,000 -142,202,000 -165,291,000 358,172,000 374,828,000 -16,656,000 -149,554,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$146,621,000
NetIncome TTM
$-224,740,000
OpCashFlow TTM
—
Assets (Latest)
$111,317,000
Forward EPS
$-1.92

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
2026-11-17 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.